Immune

Forte, First Tracks soar on CD122 success in vitiligo; celiac next

Thu, 09 Jul 2026 12:00:00 -0400

Encouraging phase I data this week of new treatments for vitiligo, a chronic autoimmune disorder that destroys melanocytes, drove investor excitement, with Forte Biosciences Inc. the latest company to disclose a statistically significant benefit.

Microbial ecology reshapes cancer care, diagnostics and therapies

Wed, 08 Jul 2026 09:00:00 -0400

Cancer researchers are increasingly turning to the microbiome to understand why some patients respond well to treatment while others face severe complications. Gut microbial communities shift during intensive therapies such as bone marrow transplantation, and those changes influence infection risk, immune recovery and long‑term survival. New advances in microbial sequencing and engineering redefine this community as a measurable clinical parameter that can be monitored, modeled, and even therapeutically reshaped to improve outcomes in oncology and other conditions.

Primo Thera synthesizes new IL-6Rβ inhibitors

Thu, 02 Jul 2026 09:00:00 -0400

Primo Thera Co. Ltd. has divulged new interleukin-6 receptor subunit β (IL-6Rβ; gp130) inhibitors potentially useful for the treatment of autoimmune disease.

Abera’s intranasal influenza vaccine shows promise in ferrets

Thu, 02 Jul 2026 09:00:00 -0400

Abera Bioscience AB has completed a ferret study with its intranasal influenza vaccine candidate. The results were consistently strong and encourage the continued development of the program. Abera intends to publish detailed study data in a peer-reviewed scientific journal.

In 2nd deal of week, Ipsen buys Memo’s kidney transplant antibody

Wed, 01 Jul 2026 12:00:00 -0400

Ipsen SA announced its second acquisition of the week, saying it will pay €700 million (US$797 million) for Memo Therapeutics AG and its phase III-ready drug potravitug, a treatment for BK virus-associated infections and nephropathy in immune-compromised kidney transplant patients.

Nuvectis shares continue to rally after $1.46B Haisco deal

Tue, 30 Jun 2026 12:00:00 -0400

Nuvectis Pharma Inc.’s shares climbed further after the oncology-focused biotech nabbed select rights to a late-stage complement factor B inhibitor (HSK-39297/NXP-100) and a phase I BRAF inhibitor (HSK-42360/NXP-200) from Haisco Pharmaceutical Group Co. Ltd. for $40 million up front.

NEJM paper on Tavneos pivotal trial retracted by academic authors

Tue, 30 Jun 2026 12:00:00 -0400

The academic authors of the paper describing the pivotal trial of Amgen Inc.’s Tavneos (avacopan) have retracted it from The New England Journal of Medicine because the primary endpoint assessments of nine patients were “re-adjudicated” after the database was locked and the study unblinded.

CINP 2026: Gut microbiota could predict antidepressant response

Tue, 30 Jun 2026 09:00:00 -0400

The gut microbiota may be altered in people with depression as a result of treatment. These microorganisms reorganize differently in individuals who respond to therapy. In a multiomics study of antidepressant-naive patients presented at the 2026 World Congress of Neuropsychopharmacology (CINP), scientists from National Taiwan University found that patients who improved after antidepressant treatment maintained a more balanced and functional microbial ecosystem, recovered beneficial metabolites, and displayed blood-based biological signals that aligned with these changes.

Deerfield-backed Boulevard, Metis pen $1.6B trispecific TCE deal

Tue, 30 Jun 2026 09:00:00 -0400

A U.S. biotechnology company founded by Deerfield Management Company L.P. licensed exclusive rights to Metis Techbio Co. Ltd.’s preclinical trispecific T-cell engager (TCE) for autoimmune disorders in a potential $1.62 billion deal.

EMA reverses its stance on Acadia’s Rett syndrome therapy Daybu

Mon, 29 Jun 2026 12:00:00 -0400

Following an initial rebuff in February 2026, the EMA’s Committee for Medicinal Products for Human Use (CHMP) is recommending approval of Acadia Pharmaceuticals Inc.’s Daybu (trofinetide) for treating neurobehavioral symptoms of Rett syndrome, after it took another look at the file.

CINP 2026: Gut microbiota could predict antidepressant response

Mon, 29 Jun 2026 09:00:00 -0400

EMA to pull Amgen’s Tavneos over ‘incorrect and misleading’ data

Fri, 26 Jun 2026 12:00:00 -0400

The EMA is recommending withdrawing Amgen Inc.’s complement inhibitor Tavneos (avacopan) from the market in Europe, saying data provided at the time it assessed the MAA “were found to be incorrect and misleading and could no longer be relied upon for demonstrating Tavneos’ effectiveness.”

Oblenio’s $62M series B for trispecific antibody in autoimmune diseases

Fri, 26 Jun 2026 09:00:00 -0400

A year and a half from its formation, Oblenio Bio has generated positive nonhuman primate data for LBL-051 in chronic autoimmune diseases and closed a $62 million series B to move the trispecific T-cell engager into the clinic.

Series A financing at RQ Bio to advance RQB-01 for flu prevention

Thu, 25 Jun 2026 09:00:00 -0400

RQ Biotechnology Ltd. has completed an oversubscribed $115 million (£85.5 million) series A financing to advance its long-acting antibody therapeutics for the prevention of influenza in high-risk and immunocompromised populations.

Nuvectis shares continue to rally after $1.46B Haisco deal

Wed, 24 Jun 2026 12:00:00 -0400

Pulmonary inflammation unveils three severe pneumonia subtypes

Wed, 24 Jun 2026 09:00:00 -0400

Molecular subtyping of disease is typically associated with cancer. Now, researchers at the University of Cambridge are applying it to infections.

Cynata’s Cymerus flops in osteoarthritis, GVHD

Tue, 23 Jun 2026 12:00:00 -0400

Neither of Cynata Therapeutics Ltd.’s pivotal trials for its Cymerus stem cell platform met the primary endpoints, with no statistically significant differences between active and control groups on primary or key secondary efficacy measures, CEO Kilian Kelly told investors during a June 22 conference call.

J-Pharma drives first cancer LAT1 to phase III study with FDA nod

Tue, 23 Jun 2026 12:00:00 -0400

J-Pharma Co. Ltd. is progressing the most clinically advanced L-type amino acid transport 1 (LAT1) inhibitor, nanvuranlat (JPH‑203), in a global phase III Beacon-BTC study of biliary tract cancer following U.S. FDA alignment.

K2 nabs two Antengene bispecific TCEs in $2B license, option deal

Tue, 23 Jun 2026 09:00:00 -0400

MPM Bioimpact-spawned K2 Therapeutics Inc. inked a license deal plus option agreement, worth $980.5 million apiece, to gain ex-China rights to two of Antengene Corp. Ltd.’s preclinical anticancer bispecific T-cell engager (TCE) assets. The deal, announced June 21, will grant Singapore-based K2 exclusive rights to develop and commercialize Antengene’s ATG-106 outside of mainland China, Hong Kong, Macau and Taiwan.

Pulmonary inflammation unveils three severe pneumonia subtypes

Tue, 23 Jun 2026 09:00:00 -0400

Molecular subtyping of disease is typically associated with cancer. Now, researchers at the University of Cambridge are applying it to infections. Some patients with severe pneumonia progress in different ways. Predicting their trajectories could help tailor treatments and prevent fatal outcomes. To do this, the scientists analyzed bronchoalveolar fluid from several patient cohorts and identified three biological pneumotypes based on which cells are present, which genes are active, and which inflammatory proteins are produced.

Cynata’s Cymerus flops in osteoarthritis, GVHD

Mon, 22 Jun 2026 12:00:00 -0400

Bionyra closes $165M series A to develop antibodies for inflammation

Mon, 22 Jun 2026 12:00:00 -0400

Bionyra Pharma has emerged with a $165 million oversubscribed series A and a portfolio of three antibodies with extended half-lives that are designed to offer improvements over existing classes of monoclonal antibodies for treating chronic inflammatory diseases.

Abbvie pads immunology pipeline in $10.9B Apogee buy

Mon, 22 Jun 2026 12:00:00 -0400

In a deal viewed as a big win for both companies, Abbvie Inc. is buying Apogee Therapeutics Inc. for $10.9 billion. The transaction calls for shareholders of Apogee to receive $135.11 per share in cash, marking a nearly 50% premium over Friday’s closing stock price, and puts lead candidate zumilokibart, a late-stage, half-life extended monoclonal antibody targeting IL-13 that has shown competitive phase II data in atopic dermatitis, in the hands of a pharma giant with a well-established immunology franchise.

Grant supports Replicate’s srRNA vaccine development for TB

Mon, 22 Jun 2026 09:00:00 -0400

Replicate Bioscience Inc. has been awarded a new grant worth approximately $3 million from the Gates Foundation to accelerate the development of globally accessible tuberculosis (TB) vaccines using Replicate’s clinically validated self-replicating RNA (srRNA) platform.

K2 nabs two Antengene bispecific TCEs in $2B license, option deal

Mon, 22 Jun 2026 09:00:00 -0400

Biogen pads immune pipeline with $1B Raythera buy

Thu, 18 Jun 2026 12:00:00 -0400

Details were scant, but Biogen Inc. snagged a portfolio of early stage immunology-focused candidates by way of an acquisition deal for Raythera Inc. that could total as much as $1 billion.

J-Pharma drives first cancer LAT1 to phase III study with FDA nod

Thu, 18 Jun 2026 12:00:00 -0400

CEPI extends support for Abera’s vaccine platform

Thu, 18 Jun 2026 09:00:00 -0400

Abera Bioscience AB has announced the decision by CEPI (Coalition for Epidemic Preparedness Innovations) to extend the ongoing project supporting the development of Abera’s BERA vaccine platform and the company’s influenza vaccine candidate. The project period has been extended until Dec. 31, 2026, with the budget unchanged.

Spyre’s Skyline-UC double win lifts hopes for IBD antibody combos

Wed, 17 Jun 2026 12:00:00 -0400

Spyre Therapeutics Inc.’s striking “two for two” data on ulcerative colitis (UC) candidates, SPY-001 and SPY-002, drew applause from multiple analysts, putting eyes on the Boston biotech’s upcoming top-line data of anti-IL-23 antibody SPY-003 – the third biologic module in a six-strong inflammatory bowel disease (IBD) lineup.

Three deals in six days: Everest builds late-stage APAC portfolio

Tue, 16 Jun 2026 12:00:00 -0400

Fresh off a deal with Travere Therapeutics Inc. for civorebrutinib worth more than $1.14 billion, Everest Medicines Ltd. went on a shopping spree, striking three deals in six days to expand its pipeline and geographic reach across Asia Pacific.